FindTrial
Sign In

EFFICACY OF FARICIMAB IN PATIENTS WITH SUBRETINAL HYPERREFLECTIVE MATERIAL ASSOCIATED WITH TYPE 2 OR MIXED NEOVASCULAR MEMBRANES ASSESSED BY MULTIMODAL IMAGING

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522701-38-00
Acronym
FARIDUO
Enrollment
100
Registered
2025-12-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SUBRETINAL HYPERREFLECTIVE MATERIAL

Brief summary

Resolution of SHRM at week 16

Interventions

DRUGVabysmo 120 mg/mL solution for injection in pre-filled syringe

Sponsors

Asociacion Instituto De Investigacion Sanitaria Biobizkaia
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Resolution of SHRM at week 16—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026